The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision
Abstract
Cyclophosphamide (CP) is an important anticancer drug which belongs to the class of alkylating agent. Cyclophosphamide is mostly used in bone marrow transplantation, rheumatoid arthritis, lupus erythematosus, multiple sclerosis, neuroblastoma and other types of cancer. Dose‐related cardiotoxicity is a limiting factor for its use. CP‐induced cardiotoxicity ranges from 7 to 28% and mortality ranges from 11 to 43% at the therapeutic dose of 170–180 mg/kg, i.v. CP undergoes hepatic metabolism that results in the production of aldophosphamide. Aldophosphamide decomposes into phosphoramide mustard & acrolein. Phosphoramide is an active neoplastic agent, and acrolein is a toxic metabolite which acts on the myocardium and endothelial cells. This is the first review article that talks about cyclophosphamide‐induced cardiotoxicity and the different signaling pathways involved in its pathogenicity. Based on the available literature, CP is accountable for cardiomyocytes energy pool alteration by affecting the heart fatty acid binding proteins (H‐FABP). CP has been found associated with cardiomyocytes apoptosis, inflammation, endothelial dysfunction, calcium dysregulation, endoplasmic reticulum damage, and mitochondrial damage. Molecular mechanism of cardiotoxicity has been discussed in detail through crosstalk of Nrf2/ARE, Akt/GSK‐3&bgr;/NFAT/calcineurin, p53/p38MAPK, NF‐kB/TLR‐4, and Phospholamban/SERCA‐2a signaling pathway. Based on the available literature we support the fact that metabolites of CP are responsible for cardiotoxicity due to depletion of antioxidants/ATP level, altered contractility, damaged endothelium and enhanced pro‐inflammatory/pro‐apoptotic activities resulting into cardiomyopathy, myocardial infarction, and heart failure. Dose adjustment, elimination/excretion of acrolein and maintenance of endogenous antioxidant pool could be the therapeutic approach to mitigate the toxicities. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Oxidative stress, antioxidants and stress tolerance
Mittler, R. (2002) · Trends in Plant Science · doi:10.1016/s1360-1385(02)02312-9 · Cited by 10,764
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Mediators of endoplasmic reticulum stress-induced apoptosis
Szegezdi, E., Logue, S. E., Gorman, A. M., & Samali, A. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400779 · Cited by 2,345
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Furuhashi, M., & Hotamisligil, G. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2589 · Cited by 1,785
Carnitine—metabolism and functions
Bremer, J. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.4.1420 · Cited by 1,666
(2006) · Surgery · doi:10.1016/s0039-6060(06)00616-7 · Cited by 1,642
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Caspases in apoptosis and beyond
Li, J., & Yuan, J. (2008) · Oncogene · doi:10.1038/onc.2008.297 · Cited by 1,090
Boyle, W. J., Smeal, T., Defize, L. H. K., Angel, P., Woodgett, J. R., Karin, M., & Hunter, T. (1991) · Cell · doi:10.1016/0092-8674(91)90241-p · Cited by 1,055
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Korsmeyer, S. J., Wei, M. C., Saito, M., Weiler, S., Oh, K. J., & Schlesinger, P. H. (2000) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400783 · Cited by 1,034
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Cardiac Fibroblast: The Renaissance Cell
Souders, C. A., Bowers, S. L. K., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 984
Thomas, E., Buckner, C., Banaji, M., Clift, R., Fefer, A., Flournoy, N., Goodell, B., Hickman, R., Lerner, K., Neiman, P., et al. (1977) · Blood · doi:10.1182/blood.v49.4.511.511 · Cited by 979
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814
Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T., & Kinoshita, M. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70041-9 · Cited by 791
van Laar, J. M., Farge, D., Sont, J. K., Naraghi, K., Marjanovic, Z., Larghero, J., Schuerwegh, A. J., Marijt, E. W. A., Vonk, M. C., Schattenberg, A. V., et al. (2014) · JAMA · doi:10.1001/jama.2014.6368 · Cited by 766
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761
Deanfield, J., Donald, A., Ferri, C., Giannattasio, C., Halcox, J., Halligan, S., Lerman, A., Mancia, G., Oliver, J. J., Pessina, A. C., et al. (2005) · Journal of Hypertension · doi:10.1097/00004872-200501000-00004 · Cited by 634
Tsung, A., Klune, J. R., Zhang, X., Jeyabalan, G., Cao, Z., Peng, X., Stolz, D. B., Geller, D. A., Rosengart, M. R., & Billiar, T. R. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070247 · Cited by 620
Reactive oxygen species are downstream mediators of p53-dependent apoptosis.
Johnson, T. M., Yu, Z. X., Ferrans, V. J., Lowenstein, R. A., & Finkel, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11848 · Cited by 596
Mitochondrial calcium overload is a key determinant in heart failure
Santulli, G., Xie, W., Reiken, S. R., & Marks, A. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513047112 · Cited by 558
Molecular Mechanisms of Acrolein Toxicity: Relevance to Human Disease
Moghe, A., Ghare, S., Lamoreau, B., Mohammad, M., Barve, S., McClain, C., & Joshi-Barve, S. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu233 · Cited by 511
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
Gottdiener, J. S. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.141.6.758 · Cited by 486
Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation
Thornton, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronshtam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., et al. (2008) · Science · doi:10.1126/science.1156037 · Cited by 484
Fibroblasts and Myofibroblasts: What Are We Talking About?
Baum, J., & Duffy, H. S. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182116e39 · Cited by 481
Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo
Antos, C. L., McKinsey, T. A., Frey, N., Kutschke, W., McAnally, J., Shelton, J. M., Richardson, J. A., Hill, J. A., & Olson, E. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231619298 · Cited by 477
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment
Lenneman, C. G., & Sawyer, D. B. (2016) · Circulation Research · doi:10.1161/circresaha.115.303633 · Cited by 469
Fillmore, N., Mori, J., & Lopaschuk, G. D. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12475 · Cited by 468
Griendling, K. K., Touyz, R. M., Zweier, J. L., Dikalov, S., Chilian, W., Chen, Y.-R., Harrison, D. G., & Bhatnagar, A. (2016) · Circulation Research · doi:10.1161/res.0000000000000110 · Cited by 444
Glycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
The ubiquitous role of nitric oxide in cardioprotection
Jones, S. P., & Bolli, R. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.011 · Cited by 434
Glycogen Synthase Kinase-3β Is a Negative Regulator of Cardiomyocyte Hypertrophy
Haq, S., Choukroun, G., Kang, Z. B., Ranu, H., Matsui, T., Rosenzweig, A., Molkentin, J. D., Alessandrini, A., Woodgett, J., Hajjar, R., et al. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.1.117 · Cited by 392
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
Goldberg, M., Antin, J., Guinan, E., & Rappeport, J. (1986) · Blood · doi:10.1182/blood.v68.5.1114.1114 · Cited by 371
Jensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 336
Braz, J. C., Bueno, O. F., Liang, Q., Wilkins, B. J., Dai, Y.-S., Parsons, S., Braunwart, J., Glascock, B. J., Klevitsky, R., Kimball, T. F., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17295 · Cited by 332
Welsh, G. I., Miller, C. M., Loughlin, A. J., & Price, N. T. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01548-2 · Cited by 298
Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association
Taegtmeyer, H., Young, M. E., Lopaschuk, G. D., Abel, E. D., Brunengraber, H., Darley-Usmar, V., Des Rosiers, C., Gerszten, R., Glatz, J. F., Griffin, J. L., et al. (2016) · Circulation Research · doi:10.1161/res.0000000000000097 · Cited by 286
Nafees, S., Rashid, S., Ali, N., Hasan, S. K., & Sultana, S. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.02.021 · Cited by 265
Traynor, A. E., Schroeder, J., Rosa, R. M., Cheng, D., Stefka, J., Mujais, S., Baker, S., & Burt, R. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02627-1 · Cited by 245
Acrolein Exposure Is Associated With Increased Cardiovascular Disease Risk
DeJarnett, N., Conklin, D. J., Riggs, D. W., Myers, J. A., O'Toole, T. E., Hamzeh, I., Wagner, S., Chugh, A., Ramos, K. S., Srivastava, S., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000934 · Cited by 214
Gorski, P. A., Ceholski, D. K., & Hajjar, R. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.005 · Cited by 213
Ungvari, Z., Gupte, S., Recchia, F., Batkai, S., & Pacher, P. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161054368607 · Cited by 205
Nikolakaki, E., Coffer, P. J., Hemelsoet, R., Woodgett, J. R., & Defize, L. H. K. (1993) · PubMed · Cited by 188
Ramyaa, P., krishnaswamy, R., & Padma, V. V. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.024 · Cited by 185
Levis, B. E., Binkley, P. F., & Shapiro, C. L. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30535-1 · Cited by 184
Differential activation of p38MAPK isoforms by MKK6 and MKK3
Rémy, G., Risco, A. M., Iñesta-Vaquera, F., González‐Terán, B., Sabio, G., Davis, R. J., & Cuenda, A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.11.020 · Cited by 178
Extracellular Heat Shock Protein 60, Cardiac Myocytes, and Apoptosis
Kim, S.-C., Stice, J. P., Chen, L., Jung, J. S., Gupta, S., Wang, Y., Baumgarten, G., Trial, J., & Knowlton, A. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209643 · Cited by 178
Acrolein Can Cause Cardiovascular Disease: A Review
Henning, R. J., Johnson, G. T., Coyle, J. P., & Harbison, R. D. (2017) · Cardiovascular Toxicology · doi:10.1007/s12012-016-9396-5 · Cited by 178
TGF-β coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival
Gingery, A., Bradley, E. W., Pederson, L., Ruan, M., Horwood, N. J., & Oursler, M. J. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.06.006 · Cited by 175
Chemotherapy-Induced Cardiotoxicity
Shaikh, A. Y., & Shih, J. A. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0083-y · Cited by 174
The Living Scar – Cardiac Fibroblasts and the Injured Heart
Rog-Zielinska, E. A., Norris, R. A., Kohl, P., & Markwald, R. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.12.006 · Cited by 171
Trastuzumab: hopes and realities
Leyland-Jones, B. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00676-9 · Cited by 169
Toll-Like Receptor-4 Deficiency Attenuates Doxorubicin-Induced Cardiomyopathy in Mice
Riad, A., Bien, S., Gratz, M., Escher, F., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., Kroemer, H. K., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.004 · Cited by 169
Florescu, M., Cintezǎ, M., & Vinereanu, D. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328349761c · Cited by 162
Huyan, X.-H., Lin, Y.-P., Gao, T., Chen, R.-Y., & Fan, Y.-M. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.04.011 · Cited by 159
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
Alexandre, J., Moslehi, J. J., Bersell, K. R., Funck‐Brentano, C., Roden, D. M., & Salem, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.009 · Cited by 157
Ghosh, J., Das, J., Manna, P., & Sil, P. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.048 · Cited by 155
Mohammad, M. K., Avila, D. V., Zhang, J., Barve, S. S., Arteel, G. E., McClain, C. J., & Joshi‐Barve, S. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.09.021 · Cited by 151
Fogli, S., Nieri, P., & Breschi, M. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-0724rev · Cited by 149
High‐dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus
Petri, M., Jones, R. J., & Brodsky, R. A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10752 · Cited by 148
Ren, S., Yang, J., Kalhorn, T. F., & Slattery, J. T. (1997) · PubMed · Cited by 146
Prospective therapeutic applications of p53 inhibitors
Gudkov, A. V., & Komarova, E. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.153 · Cited by 142
Cyclophosphamide-Induced Cardiomyopathy
Dhesi, S., Chu, M. P., Blevins, G., Paterson, I., Larratt, L. M., Oudit, G. Y., & Kim, D. H. (2013) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709613480346 · Cited by 141
Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation
Tichelli, A., Bhatia, R., & Socié, G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07165.x · Cited by 139
Origins of cardiac fibroblasts
Moore-Morris, T., Cattaneo, P., Puceat, M., & Evans, S. M. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.031 · Cited by 139
Younce, C. W., Burmeister, M. A., & Ayala, J. E. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2012 · Cited by 134
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Ghatalia, P., Morgan, C. J., Je, Y., Nguyen, P. L., Trinh, Q., Choueiri, T. K., & Sonpavde, G. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.008 · Cited by 133
Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure.
Zhang, W., Elimban, V., NIJJAR, M. S., Gupta, S. K., & Dhalla, N. S. (2003) · PubMed · Cited by 131
Shaker, R. A., Abboud, S. H., Assad, H., et al. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0184-z · Cited by 126
Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice
Srivastava, S., Sithu, S. D., Vladykovskaya, E. N., Haberzettl, P., Hoetker, D. J., Siddiqui, M. A., Conklin, D. J., D’Souza, S. E., & Bhatnagar, A. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.01.001 · Cited by 123
Son, Y., Jeong, Y.-T., Lee, K.-A., Choi, K.-H., Kim, S., Rhim, B.-Y., & Kim, K. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31815bd23d · Cited by 121
An Anniversary for Cancer Chemotherapy
Hirsch, J. (2006) · JAMA · doi:10.1001/jama.296.12.1518 · Cited by 121
Kodumudi, K. N., Weber, A. M., Sarnaik, A. A., & Pilon‐Thomas, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200274 · Cited by 117
MicroRNAs in endothelial cell homeostasis and vascular disease
Fernandez-Hernando, C. F., & Suárez, Y. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000424 · Cited by 117
Sato, Y., Kiriazis, H., Yatani, A., Schmidt, A. G., Hahn, H. H., Ferguson, D. G., Sako, H., Mitarai, S., Honda, R., Mesnard, L., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006889200 · Cited by 116
Asiri, Y. A. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.5.13107 · Cited by 114
Mitochondrial energetics and calcium coupling in the heart
Kohlhaas, M., Nickel, A. G., & Maack, C. (2017) · The Journal of Physiology · doi:10.1113/jp273609 · Cited by 113
Mantawy, E. M., Esmat, A., El‐Bakly, W. M., Din, R. A. S. E., & El‐Demerdash, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-05005-9 · Cited by 109
Gramolini, A. O., Kislinger, T., Alikhani‐Koupaei, R., Fong, V., Thompson, N. J., Isserlin, R., Sharma, P., Oudit, G. Y., Trivieri, M. G., Fagan, A., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700245-mcp200 · Cited by 108
Role of metabolites of cyclophosphamide in cardiotoxicity
Kurauchi, K., Nishikawa, T., Miyahara, E., Okamoto, Y., & Kawano, Y. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2726-2 · Cited by 107
Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy
Ismahil, M. A., Hamid, T., Haberzettl, P., Gu, Y., Chandrasekar, B., Srivastava, S., Bhatnagar, A., & Prabhu, S. D. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00120.2011 · Cited by 106
Protective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats
Omole, J. G., Ayoka, A. O., Alabi, Q. K., Adefisayo, M. A., Asafa, M. A., Babalola, O. O., & Fadeyi, B. A. (2018) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2156587218757649 · Cited by 106
Wang, G.-W., Guo, Y., Vondriska, T. M., Zhang, J., Zhang, S., Tsai, L. L., Zong, C., Bolli, R., Bhatnagar, A., & Prabhu, S. D. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.03.020 · Cited by 105
Swamy, A. H. V., Patel, U. M., Koti, B., Gadad, P. C., Patel, N. L., & Thippeswamy, A. H. M. (2013) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.106434 · Cited by 102
Bao, W., Behm, D. J., Nerurkar, S. S., Ao, Z., Bentley, R. G., Mirabile, R. C., Johns, D. G., Woods, T. N., Doe, C. P. A., Coatney, R. W., et al. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318046f34a · Cited by 100
Cardiac Muscle Ring Finger-1 Increases Susceptibility to Heart Failure In Vivo
Willis, M. S., Schisler, J. C., Li, L., Rodriguez, J., Hilliard, E., Charles, P. C., & Patterson, C. (2009) · Circulation Research · doi:10.1161/circresaha.109.194928 · Cited by 100
Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages
O’Toole, T. E., Zheng, Y., Hellmann, J. L., Conklin, D. J., Barski, O. A., & Bhatnagar, A. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.01.024 · Cited by 98
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
Bass, K. K., & Mastrangelo, M. J. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050498 · Cited by 96
Gómez‐Sintes, R., & Lucas, J. J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37873 · Cited by 95
Tripathi, D. N., & Jena, G. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00756.x · Cited by 94
Chong, E., Chang, S.-L., Hsiao, Y.-W., Singhal, R., Liu, S.-H., Leha, T., Lin, W.-Y., Hsu, C.-P., Chen, Y.-C., Chen, Y.-J., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.01.044 · Cited by 93
Wang, X., Cui, L., Joseph, J., Jiang, B., Pimental, D. R., Handy, D. E., Liao, R., & Loscalzo, J. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.12.009 · Cited by 91
GSK-3 mouse models to study neuronal apoptosis and neurodegeneration
Gómez‐Sintes, R., Hernández, F., Lucas, J. J., & Avila, J. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00045 · Cited by 91
Murray, D. B., Gardner, J. D., Brower, G. L., & Janicki, J. S. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00048.2004 · Cited by 91
Mayourian, J., Ceholski, D. K., Gonzalez, D. M., Cashman, T. J., Sahoo, S., Hajjar, R. J., & Costa, K. D. (2018) · Circulation Research · doi:10.1161/circresaha.117.311589 · Cited by 91
Thandavarayan, R. A., Watanabe, K., Ma, M., Gurusamy, N., Veeraveedu, P. T., Konishi, T., Zhang, S., Muslin, A. J., Kodama, M., & Aizawa, Y. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00124.2009 · Cited by 90
Jnaneshwari, S., Hemshekhar, M., Santhosh, M. S., Sunitha, K., Thushara, R. M., Thirunavukkarasu, C., Kemparaju, K., & Girish, K. S. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12016 · Cited by 89
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure
Dietl, A., & Maack, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0347-7 · Cited by 89
Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
Florido, R., Smith, K. L., Cuomo, K. K., & Russell, S. D. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006915 · Cited by 88
Dı́az-Araya, G., Vivar, R., Humeres, C. D., Boza, P., Bolívar, S., & Muñoz, C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.001 · Cited by 87
Morandi, P., Ruffini, P., Benvenuto, G., Vecchia, L. L., Mezzena, G., & Raimondi, R. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703132 · Cited by 84
Cardiac changes with cyclophosphamide
Steinherz, L. J., Steinherz, P. G., Mangiacasale, D., O’Reilly, R. J., Allen, J. C., Sorell, M., & Miller, D. R. (1981) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950090502 · Cited by 83
Sudharsan, P. T., Mythili, Y., Selvakumar, E., & Varalakshmi, P. (2005) · Human & Experimental Toxicology · doi:10.1191/0960327105ht530oa · Cited by 80
Brockstein, B., Smiley, C. M., Al‐Sadir, J., & Williams, S. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702234 · Cited by 79
Marrow transplanation in man following cyclophosphamide.
Santos, G., Sensenbrenner, L., Burke, P., Colvin, M., Owens, A. H., Bias, W. Β., & Slavin, R. E. (1971) · PubMed · Cited by 79
Cardioprotective effects of rhamnetin in H9c2 cardiomyoblast cells under H2O2-induced apoptosis
Park, E.-S., Kang, J. C., Jang, Y. C., Park, J. S., Jang, S. Y., Kim, D.-E., Kim, B., & Shin, H. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.02.019 · Cited by 78
Transforming growth factor‐β stimulates epithelial–mesenchymal transformation in the proepicardium
Olivey, H. E., Mundell, N. A., Austin, A. F., & Barnett, J. V. (2005) · Developmental Dynamics · doi:10.1002/dvdy.20593 · Cited by 78
Wheat, L. A., Haberzettl, P., Hellmann, J. L., Baba, S. P., Bertke, M., Lee, J., McCracken, J., O’Toole, T. E., Bhatnagar, A., & Conklin, D. J. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.227124 · Cited by 77
Blueberry Anthocyanins-Enriched Extracts Attenuate Cyclophosphamide-Induced Cardiac Injury
Liu, Y., Tan, D., Shi, L., Liu, X., Zhang, Y., Tong, C., Song, D., & Hou, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127813 · Cited by 76
Chua, B. H. L., & Shrago, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39907-6 · Cited by 73
Isoforms of acetyl-CoA carboxylase: structures, regulatory properties and metabolic functions
Brownsey, R. W., Zhande, R., & Boone, A. N. (1997) · Biochemical Society Transactions · doi:10.1042/bst0251232 · Cited by 72
Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate
El‐Agamy, D. S., Elkablawy, M. A., & Abo‐Haded, H. M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3233-1 · Cited by 72
Chemotherapy-induced cardiomyopathy
Higgins, A. Y., O’Halloran, T. D., & Chang, J. D. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9502-y · Cited by 71
Ciani, L., & Salinas, P. C. (2007) · BMC Cell Biology · doi:10.1186/1471-2121-8-27 · Cited by 71
Protective effect of N-acetylcysteine on cyclophosphamide-induced cardiotoxicity in rats
Mansour, H. H., kiki, S. M. E., & Hasan, H. F. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.07.013 · Cited by 71
p 38 MAPK in cardioprotection – are we there yet?
Martin, E. D., Bassi, R., & Marber, M. S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12901 · Cited by 70
Otsu, K., Yamashita, N., Nishida, K., Hirotani, S., Yamaguchi, O., Watanabe, T., Hikoso, S., Higuchi, Y., Matsumura, Y., Maruyama, M., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00096-2 · Cited by 70
Aging and endothelin: Determinants of disease
Barton, M. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.09.009 · Cited by 69
Tenhunen, O., Soini, Y., Ilves, M., Rysä, J., Tuukkanen, J., Serpi, R., Pennanen, H., Ruskoaho, H. J., & Leskinen, H. K. (2006) · The FASEB Journal · doi:10.1096/fj.05-5618fje · Cited by 69
Wnt3A Induces GSK‐3β Phosphorylation and β‐Catenin Accumulation Through RhoA/ROCK
Kim, J., Kim, M., Choi, W. B., Moon, M., Kim, H., Lee, J., Kim, J., Kim, S., Kang, S. G., Seo, G., et al. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25572 · Cited by 67
Andersson, M. C., Tobin, G., & Giglio, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.6 · Cited by 65
Liu, Y., Yang, A., Qu, Y., Wang, Z., Zhang, Y., Liu, Y., Wang, N., Teng, L., & Wang, D. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.04.178 · Cited by 60
Gore, P. R., Prajapati, C. P., Mahajan, U. B., Goyal, S. N., Belemkar, S., Ojha, S. K., & Patil, C. R. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15781 · Cited by 59
Todorova, V., Vanderpool, D. R., Blossom, S. J., Nwokedi, E., Hennings, L. J., Mrak, R. E., & Klimberg, V. S. (2009) · Nutrition · doi:10.1016/j.nut.2009.01.004 · Cited by 58
Sandhu, H., & Maddock, H. L. (2013) · Clinical Science · doi:10.1042/cs20120620 · Cited by 56
McLaughlin, D., Zhao, Y., O’Neill, K. M., Edgar, K. S., Dunne, P. D., Kearney, A. M., Grieve, D., & McDermott, B. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13773 · Cited by 55
Xu, Z., Gan, G., Liu, Y., Xiao, J., Liu, H., Mei, B., & Zhang, J. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2426-2 · Cited by 55
Maeshima, T., Honda, K., Chikazawa, M., Shibata, T., Kawai, Y., Akagawa, M., & Uchida, K. (2012) · Chemical Research in Toxicology · doi:10.1021/tx3000818 · Cited by 54
Zeng, L., Yan, Z., Ding, S., Xu, K., & Wang, L. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.06.038 · Cited by 54
Mangiferin protects rat myocardial tissue against cyclophosphamide induced cardiotoxicity
Bhatt, L. K., Sebastian, B., & Joshi, V. (2017) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2017.04.006 · Cited by 52
Jo, H., Otani, H., Jo, F., Shimazu, T., Okazaki, T., Yoshioka, K., Fujita, M., Kosaki, A., & Iwasaka, T. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05535.x · Cited by 51
Protective Effect of Silymarin against Acrolein-Induced Cardiotoxicity in Mice
Taghiabadi, E., Imenshahidi, M., Abnous, K., Mosaffa, F., Sankian, M., Memar, B., & Karimi, G. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/352091 · Cited by 51
Acrolein generation stimulates hypercontraction in isolated human blood vessels
Conklin, D. J., Bhatnagar, A., Cowley, H. R., JOHNSON, G. H., Wiechmann, R. J., Sayre, L. M., Trent, M. B., & Boor, P. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.09.009 · Cited by 51
Khan, V., Sharma, S., Bhandari, U., Sharma, N., Rishi, V., & Haque, S. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.034 · Cited by 48
Self-citationZver, S., Zadnik, V., Černelč, P., & Koželj, M. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0112-5 · Cited by 46
Acrolein Impairs the Cholesterol Transport Functions of High Density Lipoproteins
Chadwick, A. C., Holme, R. L., Chen, Y., Thomas, M. J., Sorci‐Thomas, M. G., Silverstein, R. L., Pritchard, K. A., & Sahoo, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123138 · Cited by 45
Malonyl-CoA Decarboxylase Inhibition as a Novel Approach to Treat Ischemic Heart Disease
Lopaschuk, G. D., & Stanley, W. C. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-0634-0 · Cited by 45
Angiotensin II limits NO production by upregulating arginase through a p38 MAPK–ATF-2 pathway
Shatanawi, A., Lemtalsi, T., Yao, L., Patel, C. B., Caldwell, R. B., & Caldwell, R. W. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.042 · Cited by 44
Shruthi, S. D., Vijayalaxmi, K. K., & Shenoy, K. B. (2018) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000340 · Cited by 41
Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention
Dessalvi, C. C., Deidda, M., Mele, D., Bassareo, P. P., Esposito, R., Santoro, C., Lembo, M., Galderisi, M., & Mercuro, G. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000667 · Cited by 41
Cellular Mechanisms of Acrolein-Induced Alteration in Calcium Signaling in Airway Smooth Muscle
Hyvelin, J.-M., Roux, É., Prévost, M.-C., Savineau, J., & Marthan, R. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8879 · Cited by 39
Ifosfamide and Cyclophosphamide: Effects on Immunosurveillance
Binotto, G., Trentin, L., & Semenzato, G. (2003) · Oncology · doi:10.1159/000073353 · Cited by 39
Wang, L., Sun, Y., Asahi, M., & Otsu, K. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9169-5 · Cited by 38
Crouch, M.-L., Knowels, G. M., Stuppard, R. S., Ericson, N. G., Bielas, J. H., Marcinek, D. J., & Syrjala, K. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181086 · Cited by 37
Al-Nasser, I. A. (1998) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/s1095-6433(98)10135-6 · Cited by 36
Jiang, W., Liu, J., Li, P., Lu, Q., Pei, X., Sun, Y., Wang, G., & Hao, K. (2017) · Oncotarget · doi:10.18632/oncotarget.16629 · Cited by 36
Omega-3 Fatty Acid Protects Against Arsenic Trioxide-Induced Cardiotoxicity In Vitro and In Vivo
Varghese, M. V., Abhilash, M., Paul, M. V. S., Alex, M., & Nair, R. H. (2016) · Cardiovascular Toxicology · doi:10.1007/s12012-016-9361-3 · Cited by 35
Distinct regulation of B-type natriuretic peptide transcription by p38 MAPK isoforms
Koivisto, E., Kaikkonen, L., Tokola, H., Pikkarainen, S., Aro, J., Pennanen, H., Karvonen, T., Rysä, J., Kerkelä, R., & Ruskoaho, H. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.02.015 · Cited by 32
Current Applications of Cardiac Troponin T for the Diagnosis of Myocardial Damage
Vašatová, M., Pudil, R., Horáček, J. M., & Büchler, T. (2013) · Advances in clinical chemistry · doi:10.1016/b978-0-12-407680-8.00002-6 · Cited by 32
The effects of acetaldehyde and acrolein on muscle catabolism in C2 myotubes
Rom, O., Kaisari, S., Aizenbud, D., & Reznick, A. Z. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.024 · Cited by 31
Keßler, M., Berger, I. M., Just, S., & Rottbauer, W. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0468-7 · Cited by 29
Does p53 Inhibition Suppress Myocardial Ischemia–Reperfusion Injury?
Yano, T., Abe, K., Tanno, M., Miki, T., Kuno, A., Miura, T., & Steenbergen, C. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418763612 · Cited by 25
Lithium Inhibits GSK3β and Augments GluN2A Receptor Expression in the Prefrontal Cortex
Monaco, S. A., Ferguson, B. R., & Gao, W. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00016 · Cited by 25
Cardiotoxic effects of anthracycline?taxane combinations
Perotti, A., Cresta, S., Grasselli, G., Capri, G., Minotti, G., & Gianni, L. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.1.59 · Cited by 23
Regulation of Ca2+-ATPases,V-ATPases and F-ATPases
Chakraborti, S., & Dhalla, N. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-24780-9 · Cited by 22
Kusumoto, S., Kawano, H., Hayashi, T., Satoh, O., Yonekura, T., Eguchi, M., Takeno, M., Tsuneto, A., Koide, Y., Jo, T., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0347 · Cited by 21
Unique properties of TCR-activated p38 are necessary for NFAT-dependent T-cell activation
Alam, M. S., Gaida, M. M., Debnath, S., Tagad, H. D., Jenkins, L. M. M., Appella, E., Rahman, M. J., & Ashwell, J. D. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2004111 · Cited by 19
Decreased Cortisol and Pain in Breast Cancer: Biofield Therapy Potential
Running, A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/870640 · Cited by 15
Fabris, S. A., & MacLean, D. A. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9325-1 · Cited by 13
Ao, L., Zhai, Y., Jin, C., Cleveland, J. C., Fullerton, D. A., & Meng, X. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00204 · Cited by 13
ET (Endothelin)-1 and Ischemic Heart Disease: A Mendelian Randomization Study
Schooling, C. M., Kodali, H., Li, S., & Borrell, L. N. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgenetics.117.002026 · Cited by 13
Kyle, R. A., Jacobus, S. J., Friedenberg, W. R., Slabber, C. F., Rajkumar, S. V., & Greipp, P. R. (2009) · Cancer · doi:10.1002/cncr.24221 · Cited by 11
EPOCH regimen as salvage therapy for adult T-cell leukemia–lymphoma
Toriyama, E., Imaizumi, Y., Taniguchi, H., Taguchi, J., Nakashima, J., Itonaga, H., Sato, S., Ando, K., Sawayama, Y., Hata, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2455-x · Cited by 8
Boyle, D. A. (2018) · Journal of Infusion Nursing · doi:10.1097/nan.0000000000000285 · Cited by 6
Regulation of Cardiac Sarco(endo)plasmic Reticulum Calcium-ATPases (SERCA2a) in Response to Exercise
Hamm, N. C., Stammers, A. N., Susser, S. E., Hlynsky, M. W., Kimber, D. E., Kehler, D. S., & Duhamel, T. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-24780-9_11 · Cited by 4
Effects Of Endothelin-1 On Intracellular Tetrahydrobiopterin Levels In Vascular Tissue
Cerrato, R., Crabtree, M. J., Antoniades, C. A., Kublickiene, K. R., Schiffrin, E. L., Channon, K. M., & Böhm, F. (2018) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2018.1453942 · Cited by 4
Cited by
Astrocytes and Microglia in Stress-Induced Neuroinflammation: The African Perspective
Olude, M. A., Mouihate, A., Mustapha, O. A., Farina, C., Quintana, F. J., & Olopade, J. O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795089 · Cited by 37
Metadata
- Authors
- Iqubal, A., Iqubal, M. K., Sharma, S., Ansari, M. A., Najmi, A. K., Ali, S. M., Ali, J., & Haque, S. E.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 218
- Pages
- 112-131
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2904892687
- Cited by
- 328
- References
- 173
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.